Detalhe da pesquisa
1.
Significant reduction in the incidence of non-coronavirus infections in patients with chronic lymphocytic leukemia on ibrutinib and venetoclax treatment during the COVID-19 pandemic: An additional benefit of lockdown.
Hematol Oncol
; 41(4): 683-693, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058711
2.
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia.
Int J Mol Sci
; 24(1)2022 Dec 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36613860
3.
Stop COVID Cohort: An Observational Study of 3480 Patients Admitted to the Sechenov University Hospital Network in Moscow City for Suspected Coronavirus Disease 2019 (COVID-19) Infection.
Clin Infect Dis
; 73(1): 1-11, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33035307
4.
Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
Leukemia
; 37(7): 1464-1473, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37202442
5.
COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.
Leuk Lymphoma
; 63(7): 1607-1616, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35156528